Systematic review and meta-analysis assesses risk of venous thromboembolic events associated with VEGFR-TKIs

Source: Int J Cancer Area: News There have been concerns about the risk of venous thromboembolism with the use of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) but the risk has not been clearly defined. This meta-analysis aimed to determine the incidence and relative risk (RR) of venous thromboembolic events (VTEs) associated with these agents.   The review included phase II and III prospective trials evaluating pazopanib, sunitinib, sorafenib and vandetanib that included data on VTEs. Overall, 14 studies (n= 4430) were selected for the meta-analysis and the following findings were reported:   . The incidence of VTEs related to VEGFR-TKIs was 3% (95% CI; 1.7 to 5.1%), and there was no statistically significant increase in the risk of VTEs for VEGFR-TKIs versus controls in overall population (RR= 0.912, 95% CI; 0.617 to 1.348, p = 0.643).   . Subgroup analysis did not identify significant increase in the risk of VTEs among different ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news